BTIG lowered the firm’s price target on Exact Sciences to $85 from $90 but keeps a Buy rating on the shares after its Q4 results and guidance. The earnings call was the heaviest on commentary of how to think about other lab’s business updates, the analyst tells investors in a research note. The company is laser-focused on executing its opportunities and is poised to deliver solid, profitable growth here in 2024, though the stock will trade around flat pending more visibility from “the other guys”, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EXAS:
- LLY, CVS, EXAS: Which Strong-Buy-Rated Healthcare Stock Is the Better Buy?
- Is EXAS a Buy, Before Earnings?
- BIIB, ZTS, EXAS: Which “Strong Buy” Healthcare Stock is Best?
- Exact Sciences (NASDAQ:EXAS) Announces Strong Preliminary Q4 Results and CFO Transition
- Exact Sciences says Jeff Elliott stepping down as executive VP, CFO
